Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia

NCT00159120 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2008-01-30

No results posted yet for this study

Summary

After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year. Under both conditions prodrome based early intervention take place.

Conditions

Interventions

OTHER

maintained antipsychotic treatment vs. stepwise drug discontinuation

maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV
  • German Research Network On Schizophrenia

    collaborator NETWORK
  • Janssen-Cilag Ltd.

    collaborator INDUSTRY
  • University of Bonn

    collaborator OTHER
  • Humboldt-Universität zu Berlin

    collaborator OTHER
  • Ludwig-Maximilians - University of Munich

    collaborator OTHER
  • University of Göttingen

    collaborator OTHER
  • University of Cologne

    collaborator OTHER
  • Mainz University

    collaborator OTHER
  • University Hospital Tuebingen

    collaborator OTHER
  • Universität Duisburg-Essen

    collaborator OTHER
  • University of Mannheim

    collaborator OTHER
  • University of Jena

    collaborator OTHER
  • Martin-Luther-Universität Halle-Wittenberg

    collaborator OTHER
  • RWTH Aachen University

    collaborator OTHER
  • University of Wuerzburg

    collaborator OTHER
  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Wolfgang Gaebel, Professor · Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University of Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstraße 2, 40629 Düsseldorf, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00159120 on ClinicalTrials.gov